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Abstract: Drug release rate is an important factor in determining efficacy and toxicity of 
nanoscale drug delivery systems. However, optimization of the release rate in polymeric micel-
lar nanoscale drug delivery systems has not been fully investigated. In this study NC-6301, 
a poly(ethylene glycol)-poly(aspartate) block copolymer with docetaxel (DTX) covalently 
bound via ester link, was synthesized with various numbers of DTX molecules bound to the 
polymer backbone. The number of DTX molecules was determined up to 14 to achieve an 
optimal release rate, based upon the authors’ own pharmacokinetic model using known patient 
data. Efficacy and toxicity of the formulation was then tested in animals. When administered 
three times at 4-day intervals, the maximum tolerated doses of NC-6301 and native DTX were 
50 and 10 mg/kg, respectively, in nude mice. Tissue distribution studies of NC-6301 in mice 
at 50 mg/kg revealed prolonged release of free DTX in the tumor for at least 120 hours, thus 
supporting its effectiveness. Furthermore, in cynomolgus monkeys, NC-6301 at 6 mg/kg three 
times at 2-week intervals showed marginal toxicity, whereas native DTX, at 3 mg/kg with the 
same schedule, induced significant decrease of food consumption and neutrophil count. NC-6301 
at 50 mg/kg in mice also regressed a xenografted tumor of MDA-MB-231 human breast cancer. 
Native DTX, on the other hand, produced only transient and slight regression of the same tumor 
xenograft. NC-6301 also significantly inhibited growth of OCUM-2MLN human scirrhous 
gastric carcinoma in an orthotopic mouse model. Total weight of metastatic lymph nodes was 
also reduced. In conclusion, NC-6301 with an optimized release rate improved the potency of 
DTX while reducing its toxicity.
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Introduction
Various formations of a nanoscale drug delivery system (nanoDDS), of around 100 nm 
in diameter, have been developed and have been brought into clinical use. Of these, 
polymeric, micelle-based, anticancer drugs were originally developed by Kataoka 
et al.1–3 The assumed bases of higher effectiveness and lower toxicity of anticancer 
nanoDDSs are the “enhanced permeability and retention (EPR) effect”.4
In addition to the EPR effect, the drug release rate from macromolecular DDSs 
is also critical to efficacy,5,6 for the following two reasons: (1) time course of plasma 
concentration of the naked drug is important, since it is the loaded drug that has toxic 
effects for both normal and tumor cells; (2) not all nanoDDSs reach their target tissue, 
releasing the loaded drugs in plasma. The release rate of loaded drugs with polymeric 
micelles can be optimized by various methods such as redesigning the chemical bond 
between polymer and drug; however, with liposomes, it is not easy to control release 
Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
2713
ORIGINAL RESEARCH
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJN.S31247International Journal of Nanomedicine 2012:7
rate, because they have a stable lamella of lipid bilayer on 
the surface to contain drugs.
Docetaxel (DTX) is an antineoplastic agent used for a 
number of cancers.7–10 Although both DTX and paclitaxel 
(PTX) are taxanes with antimicrotubular properties, they have 
different toxicity profiles. The authors chose DTX because 
of its lower neurotoxicity than and its superiority to PTX.11 
It has also been shown to be superior to PTX in a number of 
preclinical models; this may be because of improved cellular 
uptake and increased potency of microtubule stabilization. 
In addition DTX has a significantly lower clinical incidence 
of neurotoxicity than PTX.12 PTX produces serious gastro-
intestinal side effects,12,13 while anorexia and fatigue are the 
most common nonhematologic effects of DTX. Even so, 
the effects of DTX are less serious than those produced by 
PTX.12,13
The authors designed NC-6301 as a polymer micelle-
based nanoDDS, consisting of poly(ethylene glycol) (PEG)-
poly(aspartate) (pAsp) block copolymer14 and ester-linked 
DTX.15 The authors hypothesized that the linkage of DTX to 
polymer should increase in vivo half-life in comparison with 
a formulation of DTX made using hydrophobic interactions, 
and the increased half-life should lead to a better therapeutic 
effect because tumors are exposed to the drug for longer. 
In fact, longer exposure of tumor cells to DTX in vitro did 
produce more potent inhibition.11
NC-6301 has a unique drug release profile compared with 
other copolymer formulations of PTX instead of DTX. These 
have already been characterized and include copolymers of 
D, L-lactide and PEG,16 and poly(L-glutamic acid)-PTX.17 
Furthermore, NC-6301 was designed to release DTX for 
longer using a known effective plasma concentration in 
patients.18 This concentration is based on the authors’ phar-
macokinetic model simulation that uses published clinical 
data on DTX.18,19
The present study was designed to determine the number 
of DTX molecules required to achieve the optimal release 
rate and to investigate the in vivo efficacy of the formulation 
as compared with native DTX. The authors first confirmed 
release of DTX in human serum in vitro. Antitumor activity 
and tissue distribution of NC-6301, in nude mice xenografts 
of MDA-MB-231 human triple-negative breast tumor, were 
examined. Efficacy and tissue concentrations of NC-6301 
were compared with those of native DTX. The toxicity 
profile of NC-6301 was evaluated in cynomolgus monkeys. 
  Furthermore, the therapeutic effect of NC-6301 was assessed 
in an animal model of scirrhous gastric cancer with lymph 
node metastasis. The results supported the therapeutic advan-
tage of using NC-6301 rather than native DTX.
Material and methods
Synthesis of NC-6301
Figure 1A shows the chemical structure of NC-6301. 
The conjugate with 14 DTX molecules per polymer was 
synthesized as follows:15 protective benzyl groups of the 
β-benzyl L-aspartate units were removed by alkaline 
hydrolysis to obtain PEG-pAsp-Ac (acetyl). The block 
copolymer (500 mg or 0.035 mmol) was dissolved in 10 mL 
of dehydrated N,N-dimethylformamide. Then DTX (1.12 g 
or 1.4 mmol), N,N′-diisopropylcarbodiimide (220 µL or 
1.43 mmol), and N,N-dimethyl-4-aminopyridine (170 mg 
or 1.4 mmol) were added under argon. After stirring over-
night at room temperature, the reaction mixture was poured 
into 300 mL of mixed hexane and ethyl acetate (1:1) to 
obtain the precipitate. This was dissolved in 100 mL of 
purified water to spontaneously form polymeric micelles. 
The micelles were purified by ultrafiltration using a mem-
brane with a molecular weight limit of 100 kDa (Millipore 
Corporation, Billerica, MA) followed by lyophilization. 
The lyophilizate was dissolved in 10 mL of dehydrated 
N,N-dimethylformamide and poured into 300 mL of hexane 
and ethyl acetate mixture (1:1) to precipitate NC-6301. 
To purify NC-6301, the precipitate was treated a second 
time. Finally NC-6301 (520 mg) was obtained after drying 
under vacuum. The conjugate with twelve DTX molecules 
per polymer was obtained using PEG-pAsp-Ac containing 
100 mol% of the α-amide form of aspartic acid residues, 
whereas the conjugate with five DTX was obtained using 
DTX trihydrate instead of DTX.15 The final number of 
DTX molecules per polymer in a conjugate was deter-
mined by absorbance at 233 nm in 50% ethanol solution. 
All of the chemicals were reagent-grade products obtained 
commercially.
Micelle preparation
The NC-6301 was first dissolved in purified water to allow 
spontaneous formation of micelles (5 mg of DTX/mL 
determined by absorbance at 233 nm). The micelles were 
passed through a 0.22 µm filter (Millex®-GP PES Express; 
Millipore Corporation) and frozen at −80°C after addition 
of 10% (w/v) sucrose. After dilution with water (×10), 
particle size was measured using the cumulative method 
with a Malvern Zetasizer 3000HSA (Malvern Instruments, 
Malvern, Worcestershire, UK) at 25°C.
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Figure 1 Determination of the optimum number of docetaxel (DTX) molecules per polymer. (A) Synthesis and chemical structure of NC-6301. Weight-average molecular 
weight of poly(ethylene glycol) is 10 kDa (n = 227). The number of aspartate residues (ie, w + x + y + z) was 40. The figure is a reproduction from the authors’ patent 
application with additional detailed information for the compound used in this study. (B) Time-dependent release of DTX to total DTX conjugated (%), with formulations of 
14 (•), 12 (), and 5 () DTX molecules per polymer. (C) Plot of the values of released DTX (%) at 24 hours shown in (B) as a function of the number of DTX molecules 
per polymer; correlation efficient (R2) was 0.9987. (D) Scheme of the proposed release model of DTX from NC-6301 in vivo. The NC-6301 dose enters the central 
compartment (Vmc) via intravenous administration. NC-6301 in the central compartment (M) can be eliminated via linear (Ke) and release (Kr) pathways. The released DTX 
(P) in the central compartment (Vc) can distribute to the peripheral shallow (Q) and deep (R) compartments according to a three-compartment model. (E) The simulated 
plasma concentrations of released DTX after intravenous administration of NC-6301 based on the pharmacokinetic model, using parameters in humans. Open squares (), 
closed circles (•), and open triangles (∆) represent the time-course of released DTX when the first-order release constant of DTX from NC-6301 corresponds to 10%, 20% 
and 40% release in 24 hours, respectively. The dose of NC-6301 was set to be 100 mg/m2. The shaded area represents the range of concentrations required to inhibit cell 
growth by 50% for several cell lines.18,23,24
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Pharmacokinetic model of released DTX 
after administration of NC-6301
The plasma concentrations of released DTX after intrave-
nous administration of NC-6301 in humans were simulated 
with a compartment model, using curve fitting software 
(SCIENTIST 3.0; Micromath, Saint Louis, MO). In terms 
of released DTX, this model has first-order input and out-
put, corresponding to release of DTX from NC-6301 in the 
central compartment, and elimination of the resultant DTX. 
A three-compartment model was used to simulate elimination 
of DTX.18 The differential equations describing this compart-
ment model are (1) and (2) for the central compartment and 
(3) and (4) for the peripheral compartment (Figure 1D):
 V mc ⋅ dM/dt = − (Ke+Kr) ⋅ Vmc ⋅ M  (1)
 V c ⋅ dP/dt =   − (K12+K31+K10) ⋅ Vc ⋅ P  
+ K21 ⋅ Q + K13 ⋅ R + Kr ⋅ Vmc ⋅ M  (2)
  dQ/dt = K12 ⋅ Vc ⋅ P − K21 ⋅ Q  (3)
  dR/dt = K31 ⋅ Vc ⋅ P − K13 ⋅ R  (4)
M and P are the concentrations of NC-6301 and released 
DTX in the central compartment. Vmc and Vc are the distri-
bution volumes of the central compartment for NC-6301 
and released DTX. Ke and K10 are the first-order elimination 
constants of respective NC-6301 and released DTX from the 
central compartment. Kr is the first-order release constant 
of DTX from NC-6301 in the central compartment. K12 and 
K21 are the first-order transfer constants of released DTX 
between the central and peripheral shallow compartments. 
K13 and K31 are the first-order transfer constants of released 
DTX between the central and peripheral deep compartments. 
Q and R are the amounts of DTX in the peripheral shallow 
and deep compartments. All DTX parameter values are as 
reported elsewhere.18,19
Plasma concentrations of released DTX in humans were 
simulated using different values of Kr corresponding to 10%, 
20%, and 40% release over 24 hours (0.00439, 0.00929, and 
0.0213 h−1, respectively) under the following   conditions: 
(a) half-life of NC-6301 is 24 hours and corresponds to 
the sum of Kr and Ke, is constant and equal to 0.0289 h−1; 
(b) the distribution volume of NC-6301 is limited and close 
to plasma volume: Vmc is 1.6 L/m2.20
Dose translation between species
Dosage of DTX in humans using body surface area (mg/m2) 
was converted to weight (mg/kg) in mice and monkeys 
using US Food and Drug Administration guidelines.21 The 
authors assumed 175 cm in height and 75 kg in weight for 
humans, and 0.02 and 3.0 kg in body weight in mice and 
monkeys, respectively. For example, 35 mg/m2 in humans, 
a weekly dose currently used in clinical setting, is equivalent 
to approximately 10 mg/kg in mice, and 3 mg/kg in monkeys 
(Table 1). The pharmacokinetics of small molecule com-
pounds and those of nanoparticles are different.
Cells and animals
An MDA-MB-231 human triple-negative breast tumor was 
purchased from the European Collection of Cell Cultures 
through DS Pharma Biomedical (Osaka, Japan). An OCUM-
2MLN cell line was established from human scirrhous 
gastric carcinoma, as previously described.22 A PC-3 human 
prostate tumor was obtained from American Type Culture 
Collection through Summit Pharmaceuticals International 
(Tokyo, Japan). Nude mice (BALB/c nu/nu) and Crlj:CD1 
(ICR) mice were purchased from Charles River, Japan 
(Yokohama, Japan). Cynomolgus monkeys, 3–4 years old, 
were obtained from Ina Research, the Philippines (Binan, 
Laguna, Philippines). All of the experiments involving 
animals were performed following national ethical conduct 
guidelines for use of animals in research.
Release of DTX from NC-6301 in fresh 
human serum or phosphate buffer
NC-6301 in saline (200 µL) was added to 0.1 M sodium 
phosphate buffer (pH 7.4) or fresh human serum (800 µL) 
prewarmed at 37°C with a final DTX concentration of 
25 µg/mL. The fresh human serum used in this experiment 
was harvested, with informed consent, from the blood of 
healthy volunteers by Ina Research Inc (Ina, Japan). The 
mixtures were kept at 37°C. At given time intervals, ali-
quots of the samples (50 µL) were taken. The released DTX 
was measured by high-performance liquid chromatography 
Table 1 Dose conversion between species and units: mg/kg and 
mg/m2
Species Weight 
(kg)
Est BSA 
(m2)
Dose 
(mg/m2)
Dose 
(mg/kg)
Est total  
dose (mg)
Human 75.00 1.922 35.00 0.88 67.26
Mouse 0.02 0.007 35.00 11.60 0.23
Monkey 3.00 0.245 35.00 2.86 8.59
Notes: Calculations were made with a dose around the maximum tolerated dose 
in animals in this study and using the online tool provided by the US Food and Drug 
Administration;21 note that these values apply to native and released DTX; DTX 
conjugated to polymeric micelle does not necessarily follow the pharmacokinetics of 
small-molecule compounds, including native or released DTX.
Abbreviations: BSA, body surface area; Est, estimated.
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(HPLC) after extraction with ethyl acetate. The collection 
of blood from donors was performed in compliance with 
national guidelines and was approved by the ethics commit-
tee of Ina Research Inc.
Effect of carboxy esterase inhibitor  
and protease inhibitor cocktail
Bis (p-nitrophenyl) phosphate sodium salt (BNPP), an 
inhibitor of carboxyl esterase, was obtained from Sigma-
Aldrich (Tokyo, Japan) and stocked in dimethyl sulfoxide. 
Protease inhibitor cocktail (PIC) in dimethyl sulfoxide 
was obtained from Thermo Scientific (Rockford, IL). 
NC-6301 in saline was added, at a final DTX concentration 
of 25 µg/mL, into bovine serum containing BNPP or PIC 
at various concentrations. The mixture was kept at 37°C 
with a final bovine serum concentration of 80% (v/v). Six 
hours after start of incubation, an aliquot of the samples 
(50 µL) was taken and the released DTX concentration 
determined. DTX release inhibition ratio was calculated 
as follows: release inhibition ratio% = (1 − DTX released 
in the presence of inhibitor/DTX released in the absence 
of inhibitor) × 100.
In vitro cytotoxicity
The PC-3 and MDA-MB-231 cells were maintained in 
RPMI1640 media supplemented with 10% heat-inactivated 
fetal bovine serum at 37°C under an atmosphere of 5% 
carbon dioxide. Exponentially growing cells were typically 
seeded in 96-well plates (5000 cells/well) and cultured in 
media   overnight. Cells were then treated with either NC-6301 
or native DTX for 72 hours. A WST-8 reagent (Dojindo 
  Laboratories, Kumamoto, Japan) was added to each well and 
cell viability was calculated according to the manufacturer’s 
instructions. The drug concentration required to inhibit cell 
growth by 50% (GI50) was determined by dose-response 
curves.
Toxicity dose-finding studies
Male nude mice were intravenously administered either 
NC-6301 or native DTX three times at 4-day intervals. Doses 
were 30–75 mg/kg for NC-6301, and 5–15 mg/kg for native 
DTX (n = 2). Hereafter, doses of NC-6301 are expressed 
as DTX equivalents, mg/kg of body weight, per injection. 
Mice were observed for 32 days after first administration. 
The body weight was monitored two or three times a week. 
The maximum tolerated dose (MTD) was defined as that 
which was not lethal, and caused body weight loss of ,20% 
of original weight.
Tissue distribution of NC-6301  
in tumor-bearing mice
The MDA-MB-231 cells were suspended in a 50% Matrigel® 
(Becton, Dickinson and Company, Franklin Lakes, NJ) and 
inoculated subcutaneously into the backs of female 5-week-
old nude mice at 3 × 106 cells/100 µL/animal. When tumor 
volumes reached approximately 400 mm3, the mice were 
treated intravenously with either native DTX (10 mg/kg) or 
NC-6301 (50 mg/kg). For each drug, 15 mice were divided 
into five groups (n = 3), corresponding to 1, 24, 48, 72 and 
120 hours for NC-6301, and 0.083, 1, 6, 24, and 48 hours for 
native DTX. Immediately before sampling, the mice were 
anesthetized with ether and blood was collected from the 
heart using a heparinized syringe. Plasma was harvested by 
centrifugation at 4°C. Tumor, liver, spleen, kidney, heart, 
and lung were removed, rinsed with saline, and stored at 
−30°C until analysis.
Determination of drug concentration  
in plasma and tissue
Tissue samples were suspended in phosphate buffered saline 
(pH 7.4) at a concentration of 25% w/w and homogenized 
on ice with a Polytron PT3100 mixer (Kinematica, Lucerne, 
Switzerland). Using aliquots of the homogenates and plasma 
(50 µL), both released DTX (that released in vivo from 
NC-6301) and total DTX (that released from NC-6301 plus 
remaining NC-6301) concentrations were determined by 
HPLC. Reversed-phase HPLC was performed at 40°C on a 
Tosoh TSK-gel ODS-80TM (4.6ϕ × 150 mm) with a Tosoh 
ODS-80TM guard cartridge (Tokyo, Japan). DTX was eluted 
with 50% acetonitrile using a Waters Alliance System at a 
flow rate of 1.0 mL/minute. Detection was carried out using 
a Waters 2487 absorbance detector at 233 nm.
To determine released DTX concentration, PTX (20 µg/
mL)/50% acetonitrile (20 µL) was added to the homoge-
nates and plasma samples (50 µL) as an internal standard. 
The sample was then treated with ethyl acetate (300 µL) to 
extract the drug. After vortexing for 10 seconds, the sample 
was centrifuged for 1 minute at 5000 × g at 4°C and the clear 
supernatant obtained. The residue was treated with ethyl 
acetate once again. The recovered supernatant was com-
bined with the previous one and dried under vacuum using 
an IWAKI VEC-310 vacuum evaporator centrifuge (AGC 
Techno Glass, Funabashi, Japan) for 30 minutes at 40°C. The 
dried residue was dissolved with 50% acetonitrile (100 µL) 
and analyzed using HPLC.
To determine total DTX concentration, the samples (50 µL) 
were treated with acetonitrile (150 µL) to precipitate   proteins. 
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After centrifugation for 1 minute at 5000 g at 4°C, the 
recovered supernatant (100 µL) was alkalified with 
50 mg/mL sodium bicarbonate (200 µL). Then 30% hydro-
gen peroxide (400 µL) and dichloromethane (300 µL) 
was added and mixed for 3 hours at room temperature to 
facilitate release of DTX from NC-6301 and to extract the 
drug. The organic phase was harvested by centrifugation 
for 1 minute at 5000 g at 4°C. The resultant mixture was 
extracted with dichloromethane (300 µL) once again. The 
recovered organic phase was combined with the previous 
one and dried. PTX (20 µg/mL)/50% acetonitrile (100 µL) 
was added to the dry residue. The prepared mixture was 
analyzed using HPLC.
Evaluation of antitumor activity  
in animal models
MDA-MB-231 human breast tumor model
The MDA-MB-231 cells were inoculated subcutane-
ously into female nude mice, as described earlier. Tumor 
  volume was calculated using the following formula: tumor 
  volume = L × W2/2, where L and W are the major and 
minor dimensions, respectively. Drug treatment with seven 
mice per group started on day 27 after inoculation, when 
tumor volume reached 218 ± 20 mm3 (average plus or minus 
standard error). DTX at 10 mg/kg and NC-6301 at 50 mg/kg 
were administered by tail vein injection three times at 4-day 
intervals. The control group was untreated.
OCUM-2MLN human scirrhous gastric  
carcinoma model
A total of 5 × 106 OCUM-2MLN cells in 50 µL of phos-
phate buffered saline were inoculated into the subserosa 
of the gastric walls of male nude mice while under ether 
anesthesia. Two weeks after inoculation, the mice were exam-
ined in vivo for primary foci by opening the abdomen under 
deep anesthesia. They were then assigned to the following 
treatment groups (n = 10) for intravenous administration of 
(1)   normal saline as the vehicle control, (2) 10 mg/kg of DTX, 
(3) 50 mg/kg of NC-6301 as the lower dose, and (4) 65 mg/kg 
of NC-6301 as the higher dose, on days 0, 4, and 8 after the 
first administration. The mice were sacrificed 4 weeks after 
inoculation and were examined for primary foci size, while 
all metastatic lymph nodes were collected and measured for 
total weight.
Toxicology studies in mice
Myelotoxicity and hepatotoxicity were assessed with male 
mice (Crlj:CD1 (ICR), n = 10) intravenously   administered 
(three times at 4-day intervals) with (1) NC-6301 at 
50 mg/kg or (2) DTX at 10 mg/kg. General condition and 
body weight of the animals were observed continuously 
for 49 days after first administration. Animals from each 
group were sacrificed one by one for blood collection 
and autopsy (macroscopic observation of liver and bone 
marrow). Hematology and blood biochemistry tests were 
carried out using an ADVIA 120 automated hematology 
analyzer (Siemens Healthcare Diagnostics, Tokyo, Japan) 
and a 7180 clinical analyzer (Hitachi High-Technologies, 
Tokyo, Japan), respectively.
Toxicology study in cynomolgus monkeys
Myelotoxicity was assessed, with male cynomolgus monkeys 
aged 3–4 years (n = 3; 2.5–3.7 kg body weight) intravenously 
administered, three times at 2-week intervals, with NC-6301 
at 3 or 6 mg/kg. Native DTX was administered as a com-
parison at 3 mg/kg. Food consumption, general conditions, 
and body weight of animals were all observed continuously 
for 42 days after first administration. Blood (1 mL per time 
point) was collected weekly. Hematological testing was car-
ried out at the same time.
Statistical analysis
Statistical analysis, where applicable, was performed using 
Excel software (Microsoft, Redmond, WA). Results were 
compared by Student’s t-test and were expressed as mean 
values with standard error. Differences were considered 
statistically significant at P , 0.05. All statistical tests 
were two-sided. Effects of NC-6301 on the growth of 
OCUM-2MLN were evaluated by multivariate analysis 
of variance testing using JMP software (SAS Institute, 
Cary, NC).
Results
Determination of release rate
The authors first analyzed relations between release rates 
of DTX and the number of DTX molecules (x + z in 
Figure 1A) per polymer, 14, 12, and 5 (Figure 1B). The 
analysis revealed that the number of molecules conjugated 
and the release rate after 24 hours were inversely correlated 
(R2 = 0.9987,   Figure 1C). Next, time-dependent plasma con-
centration of DTX in humans was simulated.   Calculations 
were performed using the pharmacokinetic model shown in 
Figure 1D, by assuming a dose of NC-6301 at 100 mg/m2, 
the MTD at a once-every-3-week schedule for native DTX in 
humans,18 and release rates at 24 hours of 10%, 20%, or 40% 
(Figure 1E). Other variables are described in the Material 
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and Methods section. According to the reported appropriate 
range of plasma DTX concentration in humans18,23,24 
(Figure 1E, gray area), the authors selected a formulation 
with 14 DTX molecules per polymer molecule.
Properties of the formulation with  
14 DTX molecules per polymer, NC-6301
The release of DTX in NC-6301 with 14 DTX per poly-
mer, of which the average diameter was 120–130 nm 
(Figure 2A), from the PEG-pAsp copolymer backbone 
was compared by incubating NC-6301 at a concentration 
of 25 µg/mL in fresh human serum and sodium phosphate 
buffer (pH 7.4) at 37°C. Slow release was confirmed in both 
media (Figure 2B). Approximately 20% and 10% of the 
released DTX were observed at 24 hours in human serum and 
phosphate buffer, respectively (Figure 2B). This supported 
the selection of this conjugate, and also allowed the authors 
to estimate that spontaneous release contributed approxi-
mately a half to total drug release in human serum.
To elucidate key factors of DTX release from NC-6301, 
the release rate was examined in bovine serum in the pres-
ence of enzyme inhibitors. Figure 2C shows the concentration 
dependency of inhibitors on DTX release from NC-6301. The 
PIC exhibited dose-dependent inhibition, while BNPP did 
not. This suggests that DTX release from NC-6301 in serum 
is predominantly dependent on metabolism of NC-6301 via 
proteases.
The authors next tested actual plasma concentrations 
in vivo of total and released DTX in tumor-bearing mice 
administered NC-6301 at 50 mg/kg (Figure 2D), with native 
DTX. The NC-6301 data points closely followed the simu-
lated concentration, based on the pharmacokinetic model 
(Figure 1D). This supports the simulation model, where 
calculation for Figure 2D was done with murine data for 
parameters, and assuming a dose of 50 mg/kg. A release 
rate of 60% for NC-6301 was also assumed, which was 
data measured in murine serum for the formulation with 
14 DTX molecules per polymer after 24 hours (data not 
shown).
With regard to total DTX and native DTX (Figure 2D), 
total DTX in plasma remained over 0.1 µg/mL for 72 hours 
after administration with NC-6301. With native DTX, on the 
other hand, it remained less than 5 hours. This illustrates in 
a clear way the longer circulation of NC-6301 as compared 
with native DTX. In fact, NC-6301 increased area under 
the concentration-time curve (AUC) of total DTX plasma 
approximately 156-fold more than native DTX at equivalent 
doses (Table 2).
The authors then analyzed toxicity of NC-6301 with 
regard to body weight in healthy nude mice and determined 
the MTD of NC-6301 and native DTX. To do this, the authors 
intravenously administered native DTX at a dose of 5, 7, 10, 
12, or 15 mg/kg or NC-6301 at a dose of 30, 40, 50, 60, or 
75 mg/kg three times every 4 days (Figure 2E and F) and 
observed body weight for 32 days. Mice administered native 
DTX of 15 mg/kg (equivalent to 45.2 mg/m2 or 1.13 mg/kg in 
humans) had a significant decrease in body weight compared 
with those administered less than 15 mg/kg. With NC-6301, 
mice administered 50 mg/kg or more had significant body 
weight loss compared with those administered less than 
50 mg/kg. Following these results, the authors considered 
the MTDs of native DTX and NC-6301 to be 10 mg/kg 
  (equivalent to 30.3 mg/m2 or 0.76 mg/kg in humans) and 
50 mg/kg, respectively, when administered three times at 
4-day intervals. This MTD value in the study with mice 
for native DTX is approximately one-third of the reported 
MTD at a once-every-3-week schedule in humans,18 
although the MTD varies according to the schedule of drug 
administration.25,26 Therefore NC-6301 at 50 mg/kg and DTX 
at 10 mg/kg were used in the following studies. Maximum 
body weight loss of treated animals was slight for NC-6301 
even in mice bearing MDA-MB-231 tumor xenograft, but 
approximately 10% with native DTX (Figure 2G).
Tissue distribution and toxicity  
of NC-6301 in mice
To check whether toxicity and efficacy for NC-6301 and 
native DTX correlated with tissue drug concentrations, 
in addition to those in plasma (Figure 2D), the authors 
investigated the kinetics of NC-6301 and native DTX in 
mice bearing MDA-MB-231 tumor xenografts. The time 
courses and AUC values in several tissues are summarized 
in Figure 3 and Table 2, respectively. In tumor tissue 
(Figure 3A) total DTX peaked at 24 hours and declined 
slowly thereafter. DTX concentrations in the tumor were 
about 1 µg/g for at least 120 hours. This data supports the 
superior efficacy of NC-6301 in vivo. Large AUC values of 
DTX were observed in the liver and the spleen (Figure 3B 
and C). However, the release ratios were very restricted. 
In contrast, relatively high release ratios were observed in 
the lung and the kidney (Figure 3D and E), although AUC 
values of released DTX were comparable with those of 
native DTX. In the heart, AUC value of released DTX was 
relatively limited (Figure 3F).
We also checked in mice whether liver- or kidney-
related blood test markers were affected by three   injections 
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Figure 2 Properties of NC-6301 with 14 docetaxel (DTX) molecules per polymer: (A) size distribution – the average diameter was 120–130 nm, with minor disparities; 
(B) release of DTX as a function of time during incubation in fresh human serum (•) or sodium phosphate buffer (pH 7.4) () at 37°C*; (C) concentration dependency of 
carboxy esterase inhibitor (bis (p-nitrophenyl) phosphate sodium salt [BNPP], ) and protease inhibitor cocktail (PIC, •) on the release of DTX. NC-6301 was incubated 
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high-performance liquid chromatography.** (D) Actual plasma DTX level in tumor-bearing mice compared with the simulated values (dashed line for total DTX and solid 
line for released DTX) based on the model shown in Figure 1D. For actual data, plasma concentration-time profiles of total (•) and released DTX () after intravenous 
administration of NC-6301 to nude mice bearing MDA-MB-231 breast tumor at 50 mg of DTX/kg. Profiles of DTX after DTX injection at 10 mg/kg (∆) are also shown for 
comparison. (E–G) Body weight changes: healthy nude mice received either DTX (E) or NC-6301 (F) intravenously three times with a 4-day interval (indicated by arrows) 
for determining the maximum tolerated dose.*** Body weight changes in nude mice bearing MDA-MB-231 tumor xenograft (G). The animals were also tested with regimens 
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Notes: *Each point represents the mean for three samples, and bars indicate standard deviation; **the concentration units of BNPP and PIC are mM and % (v/v), respectively, 
and each point represents the mean for two or three separate experiments; ***each point represents the mean for two mice; ****each point represents the mean for seven 
mice; bars, standard errors.
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of NC-6301 at 50 mg/kg or native DTX at 10 mg/kg for 
49 days after initial administration (Tables 3 and 4). No 
significant change in the blood test markers was observed 
with either drug, aside from transient increases in aspartate 
transaminase and alanine transaminase with NC-6301. 
Hepatotoxicity was reversible and marginal, although certain 
levels of released drug were observed in spleen and liver 
after a single administration of NC-6301 (Figure 4C and D). 
Furthermore, myelosuppression was mild and transient for 
both drugs (data not shown).
Table 2 Area under the concentration-time curve (AUC) values in tissues and plasma after administration of either NC-6301 at 
50 mg/kg or docetaxel (DTX) at 10 mg/kg in nude mice xenografted with MDA-MB-231 human breast tumor
NC-6301 Native DTX
Released DTX Total DTX Percentage released* DTX ET ratio** EQ ratio***
AUC (μg/g or mL ⋅ h)
Tumor 98.8 499 19.8 12.6 1.57 8.0
Spleen 390 16897 2.3 27.3 2.86 124
Kidney 76.5 246 31.1 44.2 0.35 1.1
Liver 320 21993 1.5 40.1 1.60 110
Lung 23.1 77.8 29.7 13.6 0.34 1.1
Heart 16.1 280 5.8 9.5 0.34 5.9
Plasma 5.0 5250 0.09 6.7 0.15 156
Notes: All of the AUC values were calculated using the trapezoidal rule; *AUC of released DTX/AUC of total DTX × 100; **(AUC/dose) of released DTX/(AUC/dose) of 
native DTX; ***(AUC/dose) of total DTX/(AUC/dose) of native DTX.
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Table 3   Changes  in  activity  of  aspartate  transaminase  (AST) 
and  alanine  transaminase  (ALT)  in  mice  receiving  intravenous 
NC-6301  at  50  mg/kg  or  intravenous  docetaxel  (DTX)  at 
10 mg/kg three times at 4-day intervals
Day Control NC-6301 Native DTX
AST 
(U/L)
ALT 
(U/L)
AST 
(U/L)
ALT 
(U/L)
AST 
(U/L)
ALT 
(U/L)
1 62 22 160 74 85 28
7 51 20 139 42 239 44
10 115 27 143 34 91 23
14 52 18 611 219 62 19
21 214 37 112 34 71 24
28 99 27 100 27 65 22
35 83 30 122 39 171 46
42 71 22 87 19 83 27
49 67 23 121 28 56 22
Notes: Drug injection three times with a 4-day interval started on day 0; one mouse 
from each group was sacrificed for the blood collection.
Table 4 Changes in concentrations of creatinine (CRE) and urea nitrogen (UN) in mice receiving intravenous NC-6301 at 50 mg/kg, 
or intravenous docetaxel (DTX) at 10 mg/kg three times at 4-day intervals
Day Control NC-6301 Native DTX
CRE (mg/dL) UN (mg/dL) CRE (mg/dL) UN (mg/dL) CRE (mg/dL) UN (mg/dL)
1 0.15 32.6 0.18 25.3 0.07 26.1
7 0.17 27.5 0.11 20.0 0.17 27.1
10 0.25 48.8 0.15 26.6 0.14 25.4
14 0.17 25.4 0.17 26.1 0.20 30.5
21 0.14 24.7 0.17 39.3 0.12 20.0
28 0.12 23.8 0.10 31.2 0.15 41.4
35 0.11 23.4 0.14 26.9 0.12 28.0
42 0.12 26.8 0.10 30.2 0.11 22.1
49 0.10 20.2 0.15 29.5 0.12 23.5
Notes: Drug injection three times at 4-day intervals started on day 0; one mouse from each group was sacrificed for blood collection.
Toxicology study in cynomolgus monkeys
To evaluate toxicity of NC-6301 in a species close to 
humans, the authors used cynomolgus monkeys. Although 
the monkey experiments in this work were limited in scope, 
especially in terms of dosing, the data have been added 
for reference purposes. Based on the preliminary results 
determining the MTD in this animal (data not shown), the 
authors determined drug dose in cynomolgus monkeys as 
follows: 3 mg/kg three times at 2-week intervals for native 
DTX and NC-6301, and a higher dose of 6 mg/kg only for 
NC-6301 with the same schedule (3 mg/kg in cynomolgus 
monkeys is equivalent to 36.6 mg/m2, or to 12.2 mg/kg 
in mice and 0.92 mg/kg in humans). The higher dose of 
6 mg/kg for NC-6301 was determined on the basis of the 
human MTD of a formulation encapsulating PTX,27 where the 
MTD was approximately the same as native PTX but not as 
high as in mice. The cynomolgus monkeys exhibited adverse 
effects including gastrointestinal symptoms, especially in those 
administered native DTX at 3 mg/kg. The animals treated with 
native DTX lost up to 20% more weight than those administered 
NC-6301 (Figure 5A). A critical decrease in food consumption 
was observed in animals treated with native DTX, whereas the 
decrease was marginal in those treated with NC-6301   (Figure 5B). 
Bone marrow suppression was milder with NC-6301 com-
pared with native DTX (Figure 5C). Both white blood cell 
count and neutrophil count were significantly decreased only 
by administration of native DTX.
Antitumor effect of NC-6301
In vitro cytotoxicity was first examined using MDA-MB-231 
and PC-3 tumor cells. The authors found that the GI50 
(equivalent to DTX) of NC-6301 versus MDA-MB-231 
was 0.01 µg/mL, while that of DTX was 0.004 µg/mL. 
Similarly, for PC-3 the GI50 measurements for NC-6301 
and DTX were 0.01 and 0.004 µg/mL, respectively. This 
is because DTX release from NC-6301 is limited, although 
still pharmacologically active.
Next, the authors tested whether NC-6301 exhibited 
adequate antitumor effects compared with native DTX in a 
xenograft model using MDA-MB-231 triple-negative human 
breast cancer cells. As shown in Figure 4A, three injections of 
NC-6301 at 50 mg/kg effectively suppressed tumor growth. 
In contrast, native DTX at 10 mg/kg with the same schedule 
resulted only in transient and slight regression of the tumor. 
These results suggest the superior efficacy of NC-6301 with 
fewer side effects (Figure 2G).
We also confirmed NC-6301 efficacy with an ortho-
topic mouse model of scirrhous gastric cancer, one of 
the most devastating cancers accompanied by lymphatic 
metastasis.28,29 We used OCUM-2MLN cells derived from 
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Figure 4 Antitumor effect of NC-6301 in murine models of tumors: (A) efficacy of NC-6301 and docetaxel (DTX) against MDA-MB-231 human breast tumor. MDA-MB-231 
tumor cells (3 × 106 cells/animal) were inoculated subcutaneously into the back (day −27), and intravenous administration three times at 4-day intervals (indicated by arrows) 
started on day 0 when tumor volumes were 218 ± 20 mm3 (average plus or minus standard error). The dose of NC-6301 is expressed as equivalent to DTX.# (B–E) Efficacy 
of NC-6301 and DTX against metastatic scirrhous gastric carcinoma: (B) Tumor area at the start of drug administration (day 0) – OCUM-2MLN tumor cells (5 × 106 cells/
animal) were inoculated into the subserosa of gastric walls of the mice (day −14), and intravenous administration three times at a 4-day interval started on day 0, when tumor 
areas were 13 ± 3 mm2 in all conditions; (C) photos of the smallest and the largest tumors on day 0 (green shading represents the tumor area); (D) tumor area of primary 
foci on day 14 – the doses of NC-6301 low and high represent 50 and 65 mg/kg/injection, respectively; (E) total weight of regional lymph nodes on day 14.##
Notes: #Each point represents the mean measurement for seven mice, and bars indicate the standard error; ##each point represents the individual value, each bold line 
represents the mean measurement for ten mice, and bars indicate the standard error; control and treated groups were compared statistically. *P , 0.05; ***P , 0.001 
(Student’s t-test).
patients with scirrhous gastric cancer (Figure 4B and 
C). It would be therapeutically advantageous if we could 
increase the anticancer efficacy of DTX and decrease its 
side effects by using NC-6301 in this carcinoma, since 
monotherapy with native DTX produces response rates 
of only 20% in patients with advanced gastric cancer.30 
Figure 4D and E show the tumor area of primary foci and 
the total weight of regional lymph nodes, on day 14 after 
first drug treatment. Native DTX at 10 mg/kg and NC-6301 
at the lower dose (50 mg/kg) showed similar effects with 
primary foci, while NC-6301 at a higher dose (65 mg/kg) 
effectively reduced the tumor volume. Both native DTX 
and NC-6301, at the higher dose, significantly suppressed 
lymphatic metastases, compared with the no-drug control. 
It is noteworthy that body weight loss in animals treated 
with DTX was worse than in those treated with NC-6301 
at the higher dose (data not shown). These results support 
the potential advantage of NC-6301 over native DTX, even 
for devastating cancers such as metastatic scirrhous gastric 
carcinoma.
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Figure 5 Toxicological tests in cynomolgus monkeys treated with intravenously administered NC-6301. Male cynomolgus monkeys received NC-6301 intravenously three 
times with a 2-week interval (indicated by arrows) at either 3 or 6 mg/kg. Native docetaxel (DTX) was administered similarly as a control at 3 mg/kg. (A) Average body 
weight change; (B) average change in food consumption; (C) changes in number of white blood cells (WBCs) and number of neutrophils.
Notes: Data points indicate mean measurements for three monkeys; bars indicate standard deviation.
Discussion
NC-6301 was designed to release DTX from the   polymer 
backbone at an appropriate rate, thereby obtaining better 
efficacy and tolerance than native DTX. The best DTX 
release rate was obtained with the formulation of 14 DTX 
molecules per polymer, predicted on the basis of the 
authors’ own pharmacokinetic model (Figure 1D) and 
effective plasma concentrations published elsewhere.18 
The usability of this pharmacokinetic model, as a guide to 
human use, was confirmed by simulating plasma concen-
trations of DTX released in mice administered NC-6301 
(Figure 2D).
An effective concentration of DTX in humans is sug-
gested by GI50 values obtained against the cell lines shown 
in   Figure 1E. With regard to toxic plasma concentration 
of DTX in patients, neutropenia and increased fluid reten-
tion correlate with extended concentrations .0.2 µM 
  (approximately 0.16 µg/mL),31 whereas neutropenia with 
PTX, another taxane, correlates significantly with duration 
of PTX plasma concentration of $0.05 µM (approximately 
0.04 µg/mL).32 When considering longer plasma exposure 
of DTX at an effective concentration, the simulation results 
(Figure 1E) suggest a conjugate of 14 DTX molecules per 
polymer, which had 20% release over 24 hours in human 
serum, as the best candidate. In the present study, the authors 
have shown the potential therapeutic advantages of this 
formulation of NC-6301 over native DTX. Its antitumor 
activity, tissue distribution, and toxicology in various models 
was investigated. The results promise increased efficacy of 
NC-6301 with fewer side effects, in comparison with native 
DTX, as preclinical proof.
NC-6301 has a unique drug release profile compared 
with PTX-polymer conjugates using ester linkage. The ester 
between DTX and the pAsp backbone is thought to undergo 
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half spontaneous release. The other half of the ester may 
undergo enzyme-dependent release (Figure 2B). Although 
not extensively studied, enzyme-mediated drug release is 
dependent on proteases (Figure 2C). Here, it should be 
noted that enzyme-independent drug release may reduce 
individual differences in release of DTX from NC-6301. 
On the contrary, PTX poliglumex, a clinically evaluated 
conjugate of PTX and poly(L-glutamic acid) via an ester 
linkage, is thought to release conjugated PTX through the 
action of lysosomal protease cathepsin B.17 This suggests 
that the polymer backbone impacts the release mode of the 
conjugated drug, and thus supports the authors’ preliminary 
observation that a similar DTX conjugate, with a backbone 
of poly(L-glutamic acid), showed marginal DTX release in 
serum (data not shown).
The effectiveness of NC-6301 in tumors probably 
depends on a number of factors. Based on the pharma-
cokinetic data of this study, and other information already 
available, the following can be suggested. Both tumor 
targeting of NC-6301, attributable to the EPR effect, and 
prolonged intratumoral release of DTX at high concentra-
tion demarcate drug efficacy. In the MDA-MB-231 tumor 
model, total DTX AUC was eight times greater than native 
DTX at equivalent doses (Table 2). At equitoxic doses, 
released DTX AUC in tumor was approximately eight times 
greater than that of native DTX, supporting the superior 
efficacy of NC-6301.
The potent anticancer effect of NC-6301 may also be 
due to the sustained exposure of tumor tissue to released 
DTX. The intratumoral concentration of DTX at 120 hours 
after administration of NC-6301 was approximately 1 µg/g 
(Figure 3). According to the authors’ in vitro experiments this 
concentration is greater than the GI50 value of DTX against 
MDA-MB-231 tumor cells with a 72-hour exposure time 
(4 ng/mL). The increased efficacy of NC-6301 may also be 
explained by the sustained DTX level in blood (Figure 2D) 
as with the orthotopic model of scirrhous gastric cancer. 
Aside from the EPR effect, drug release may be another 
determinant of nanoDDS efficacy. The authors have previ-
ously shown that an even smaller polymer micelle of 65 nm 
in diameter did not independently inhibit tumor growth in 
the same model,33 whereas NC-6301 of 120–130 nm did, as 
shown in this work. As well as sizes, another difference relates 
to drug release: the 65 nm micelle does not release drug 
into the blood stream, whereas NC-6301 does. Therefore, 
nanoDDS size may not be the only determinant of efficacy: 
drug release into the blood stream may be another factor. To 
support this, the required dose in the MDA-MB-231 tumor 
model was 50 mg/kg, less than the 65 mg/kg needed for 
metastatic lesions in the OCUM-2MLN model. It may thus 
be a combination of drug release and the EPR effect that 
is important. The MDA-MB-231 model exhibits sufficient 
EPR effect because of abundant leaky tumor vasculature.34,35 
However, further study is needed to clarify the mechanisms 
behind these observations.
Although NC-6301 has a tendency to accumulate in the 
liver (Figure 3B), its side effects are less disruptive than 
native DTX. Lower doses of native DTX resulted in more 
body weight loss than higher doses of NC-6301 (Figures 2G 
and 5A). This may be because use of nanoDDSs avoids 
a concentration “surge” of DTX in blood (Figure 1E and 
2D) and/or in other tissues (Figure 3) immediately after 
  administration. Furthermore, aspartate transaminase and 
alanine transaminase values for healthy mice receiving 
NC-6301 at 50 mg/kg three times at 4-day intervals, increased 
transiently. However, the change was marginal and reversible 
(Table 3), even though a fivefold larger dose of NC-6301 was 
used when compared with native DTX.
Comparison with the few reports of nanoDDSs incor-
porating DTX36–38 will help understand the features of 
NC-6301. A PEG-DTX conjugate was prepared using PEG 
with a molecular weight of 2000.36 One molecule of DTX 
binds to PEG via ester linkage. The main purpose of this 
conjugate is to avoid use of the excipient polysorbate 80 
as a solubilizer for Taxotere® (Sanofi-Aventis US LLC, 
Bridgewater, NJ), the commercially available formulation 
of DTX. The excipient present in the formulation causes 
hypersensitivity reactions and peripheral neurotoxicity, 
the main side effect of Taxotere. This PEG-DTX forma-
tion, physically entrapping free DTX, increased total DTX 
equivalent AUC in plasma 1.8-fold that of native DTX in 
mice. NC-6301, on the other hand, increased total AUC 
156-fold that of native DTX (Table 2). Thus NC-6301 is 
likely to stay in blood longer and at a higher concentration. 
There is another PEGylated DTX, NKTR-105, produced 
by Nektar Therapeutics (San Francisco, CA).39 Although 
in phase I, its chemical structure has not been reported, 
but based on the data available, we believe NC-6301 has 
a number of advantages over NKTR-105. While body 
weight loss with NKTR-105 was approximately 19% at a 
dose effective with a tumor model, body weight loss with 
NC-6301 was approximately 9% at a comparable dose in 
an orthotopic gastric cancer model. AUC of free DTX in 
tumor tissue at the MTD was twofold more than free DTX 
solution with NKTR-105, whereas that with NC-6301 was 
eightfold.
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Conclusion
In conclusion, NC-6301 is therapeutically superior to native 
DTX, with low toxicity and other advantages, and the 
authors believe it has promise as an antitumor agent. The 
pharmacokinetic model used may also provide a useful tool 
for the design of a polymeric micelle with conjugated drugs 
of established clinical efficacy (Figure 6).
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